Lung Cancer Research Foundation Announces New Research Collaboration with AstraZeneca
Over $900,000 in Research Grants Focused on Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) and Immunotherapies
News provided by
Share this article
Share this article
NEW YORK, Feb. 23, 2021 /PRNewswire/ The Lung Cancer Research Foundation (LCRF) today announced a collaboration with AstraZeneca to fund over $900,000 in research grants focused on understanding resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and immune checkpoint inhibitors (ICIs), including therapeutic approaches to overcome these mechanisms, as well as biomarkers of immune-mediated adverse events.
Lung cancer is currently the number one cause of cancer death both in the U.S. and globally among both men and women. An estimated 625 new cases are diagnosed in the U.S. every day. As research funding grows, new treatments become available and survival rates improve. Promising new treat